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Title: The Misuse and Abuse of Ophthalmic Preparations: A Scoping Review of Clinical Case 
Presentations and Extant Literature. 
Abstract 
The emergent trend of misuse and abuse of ophthalmic drugs is a public health concern. Common 
ophthalmic preparations contain anticholinergics, antihistamines, decongestants, anaesthetics, and 
vasoconstrictive and topically applied nonsteroidal anti-inflammatory drugs. Misuse and abuse 
relates to their effect in causing euphoria, relaxation, hallucination, and reduction of depression 
symptoms. A scoping review of literature was conducted using Arksey and O’Malley’s (2005) 
framework for mapping extant literature on the current knowledge of the issue. Four themes 
emerged: abuse of cycloplegics and mydriatics, misuse and abuse of topical ophthalmic 
anaesthetics, misuse of topical ophthalmic vasoconstrictive and topically applied nonsteroidal anti-
inflammatory drugs (NSAIDs), and public and pharmacist views on ophthalmic drug 
abuse/misuse. The review underscores the complex motives for misuse and abuse, availability of 
ophthalmic products, self-medication practices, presence of co-morbidities, and low public 
awareness which harms the important role of health professionals regarding suspected misuse of 
these common products. 
Running Title: A scoping review of the abuse of ophthalmic eye drops 
Keywords: Ophthalmic preparations; abuse, misuse, community pharmacy 
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Introduction 
The use of over-the-counter (OTC) and prescription medication for non-clinical use and 
self-medication is a global public health challenge (Casati et al. 2012; Norman et al. 2016; Wazaify 
et al. 2017). OTC medications are those that do not need a prescription while prescription 
medications are those that cannot be dispensed unless a prescription is written by a physician 
(Lessenger and Feinberg 2008; Van Hout and Norman 2015; Foley et al. 2015). Whilst OTC 
medications purchased from community pharmacies can help individuals to self-treat minor 
ailments and are therefore convenient for patients and physicians, some carry risks regarding habit-
forming use, abuse, and dependence (Cooper 2013; Van Hout 2014; Van Hout and Norman 2015; 
Bergin et al. 2015; Parry et al. 2015). Common drugs of misuse and abuse have analgesic, 
anaesthetic, stimulant, or anxiolytic properties (Wazaify et al. 2017). Ability to understand and 
measure the nature of public misuse of OTC medicines are complicated and challenged by retail 
environments and the hidden and heterogeneous nature of therapeutic and non-therapeutic forms 
of misuse (Lessenger and Feinberg 2008; Cooper 2011;  Casati et al. 2012; Cooper 2013; Van 
Hout and Norman 2015). Complexities also centre on varied terminology used in the literature to 
define misuse and abuse. Misuse has been broadly defined as “problematic consumption outside 
of acceptable medical practice or medical guidelines, when self-medicating at higher doses and for 
longer than is advisable, for intoxicating purposes and when risks and adverse consequences 
outweigh the benefits” (Casati et al. 2012; Shei et al. 2014; Van Hout and Norman 2015). 
This report is about the emergent trend of misuse and abuse of ophthalmic drugs, which is 
relatively rare and under-researched in comparison to the abuse of OTC drugs (Wazaify et al. 
2017). Early warning reports and mini-reviews have highlighted the issue of recreational and self-
medicating misuse of these drugs (Kadri et al. 2010; Bersini et al. 2013; Prilutskaya and Kuliev 
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2014; Bersini et al. 2015). Most commonly reported ophthalmic preparations are those containing 
anticholinergics, antihistamines, and/or decongestants, such as tropicamide, cyclopentolate, 
naphazoline, and antazoline (Darcin et al. 2011; Wazaify et al. 2016; Ponté et al. 2017). Other 
ophthalmic drugs liable for abuse are the topical anaesthetic drugs (TADs), such as proparacaine, 
lidocaine, benoxinate (oxybuprocaine), cocaine and tetracaine, and topically applied non-steroidal 
anti-inflammatory drugs (NSAIDs) (Rapuano 1990; Flach 2001; Erdem et al. 2013; Sharifi et al. 
2013). 
Given the early warning trends around this novel form of OTC drug misuse and abuse, the 
aim of this scoping review was to understand what is currently known about the misuse and abuse 
of ophthalmic drugs. 
Methods 
Scoping review methods are increasingly popular as an accepted approach for mapping the 
extant literature on a topic (Arksey and O’Malley 2005; Anderson et al. 2008; Levac et al. 2010; 
Hidalgo Landa et al. 2011; Daudt et al. 2013; Pham et al. 2014). Given the lack of extensive review 
around the topic (Hidalgo Landa et al. 2011), the scoping review as defined by Daudt et al. (2013:8) 
is to “map the literature on a particular topic or research area and provide an opportunity to identify 
key concepts, gaps in the research, and types and sources of evidence to inform practice, 
policymaking, and research.”  This scoping review was used as part of a larger project (Arksey 
and O’Malley 2005; Levac et al. 2010) to provide a descriptive review of available literature on 
the topic of misuse and abuse of ophthalmic drugs. 
The scoping review was underpinned by the primary research question: “What do we know 
about ophthalmic abuse?” Our review process adhered to the five stage method as adapted by 
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Arskey and O’Malley (2005) which involved: 1) identifying the research question, (2) identifying 
relevant studies, (3) selecting studies, (4) charting the data, and (5) collating, summarizing, and 
reporting the results. A rigorous and transparent method was used to locate and analyse all relevant 
literature (Arksey and O Malley 2005; Rumrill et al. 2010). 
Search terms linked the terms “ophthalmic” with “abuse,” “eye drops,” “misuse,” and 
“over-the-counter” and were agreed upon by a team who have pharmacy, pharmacovigilance, and 
addiction expertise. Searches were conducted on the databases PubMed, Science Direct, Google 
Scholar, Electronic Library of Medicine, Hinari, and Cochrane Library. Limitations were set to 
human studies with no limitations on the language applied. Eligibility criteria centred on whether 
studies broadly described misuse or abuse of ophthalmic drugs. Reference lists in records were 
manually searched to identify any further studies not captured in the initial database search.  
Records were managed using the bibliographic software manager EndNote (Thomson Reuters 
2012) with duplicates removed manually.  The title and abstract of each citation were crosschecked 
to agree with the inclusion criteria reached within the team. The final data set was then created by 
procuring full text versions (Levac et al. 2010). The flowchart illustrating the process is presented 
in Figure. 1. 
Insert Figure 1 about here 
The search identified 4,483 citations, of which 54 were identified to directly relate to the misuse 
and abuse of ophthalmic drugs. These were then charted into themes by the team. 
Results 
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Four themes emerged: abuse of cycloplegics and mydriatics, misuse and abuse of topical 
ophthalmic anaesthetics, misuse of topical ophthalmic vasoconstrictive and topically applied 
nonsteroidal anti-inflammatory drugs (NSAIDs), and public and pharmacist views on ophthalmic 
drug abuse/misuse. See Table 1.  
 
Abuse of Cycloplegics and Mydriatics 
The abuse of cycloplegics and mydriatics was observed in the case literature, with the first 
reported case in 1973 where a 25-year-old male with bilateral epithelial keratitis was initially 
treated with topical antibiotics, steroids, tropicamide, and cyclopentolate 1%. Drug induced 
toxicity was speculated to have contributed to keratitis, with the patient reporting application of 
100-200 drops of cyclopentolate and tropicamide many times a day (Ostler 1975). Weight loss and 
continual sleep were reported. On cessation, keratitis resolved within four days but with 
withdrawal symptoms of excessive salivation, tremors, rigidity, nausea, vomiting, and anxiety. 
Darcin et al. (2011) reported the case of a 28-year-old male patient who abused cyclopentolate 
hydrochloride. He said that he liked the burning effect of the  eye drop which made him feel “high” 
and described tolerance and dose escalation on repeated use. Withdrawal symptomatologies on 
attempts to cease use included nausea and sweating. Abuse of cyclopentolate eye drops and alcohol 
was reported by Akkaya (2008) who described a 39-year-old male case with Behcet’s disease and 
correlated vision disorder. This patient abused cyclopentolate eye drops and alcohol for 15 years 
and increased the dose to 100 drops per day. He reported blurred vision, impaired concentration, 
loss of interest, and increased anxiety when attempting to decrease or abstain from the dose. 
Treatment for dependency was successful for alcohol but not for eye drops, and the patient 
continued with the use of 100 drops per day. Sato et al. (1992) reported on two female cases of 
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cyclopentolate abuse, both administering between 100 and 400 drops per day, and with typical 
withdrawal symptoms of tremors, weakness, nausea, and vomiting. The first case aged 18 years 
had a conjunctival infection and corneal epithelial keratitis and within four months of abuse 
underwent psychiatric intervention. The second case aged 30 years had pan uveitis and multifocal 
choroiditis with a co-dependency on alcohol. Lately, Görgülü et al. (2015) reported a case for a 
28-year-old male patient with a history of bipolar disease, depression, and manic disorders since 
he was 20. Cyclopentolate eye drops were suggested by his friend to improve his symptoms of 
depression. In contrast to previous case presentation, intranasal administration was used with up 
to 100 drops each day. Cravings, manic episodes, and mood elevation were the driving forces to 
continue this use. 
Several cases of tropicamide abuse through intra-venous (IV) injection have been reported 
online (Bersani et al. 2013) and in Turkey (Bozkurt et al. 2014), Italy (Spagnolo et al. 2013), 
France (Ponté et al. 2017), Tajikistan (Otiashvili et al. 2016), and Kazakhstan (Prilutskaya and 
Kuliev 2015). Abuse is associated with blurred vision, dissociation, loss of concentration, weight 
loss, slurred speech, hallucinations, suicidal feelings, and forgetfulness (Bersini et al. 2015). 
Descriptions of user experiences ranged from pleasurable to fear inducing, and the primary 
reported motives for IV abuse were for intensifying the pleasurable effect of heroin, marijuana, 
and alcohol and delaying or minimizing heroin withdrawal symptoms (Bersani et al. 2013; Bersani 
et al. 2015). 
Prilutskaya and Kuliev (2015) in their observational study described clinical characteristics 
of patients (n=118) with poly-drug dependence, which included tropicamide.  Otiashvili et al. 
(2016) conducted 12 focus groups with 100 male participants at needle exchanges in Khorog and 
Kulob, where one participant reported using tropicamide to relieve opiate withdrawals.   The first 
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patient case of IV injection was reported in Italy (Spagnolo et al. 2013), where a heroin dependent 
22-year-old female entered a methadone substitution programme and was admitted with 
palpitations and visual and auditory hallucinations. She reported injecting 1% tropicamide-
containing eye drops for two years in order to self-manage opiate and methadone withdrawals and 
experience the euphoric effect.  During this timeframe the dose was increased from 50 ml to 150 
ml per day. Visual and auditory hallucinations were described on injection of higher doses.The 
patient later underwent a successful detoxification (Spagnolo et al. 2013). Two cases of IV use of 
tropicamide were reported in Turkey by Bozkurt et al. (2015). The first case was an unemployed 
37-year-old male, long term poly-drug user (heroin, clonazepam, ecstasy, cocaine, biperiden) who 
reported mixing 0.25 mg heroin with 1 ml tropicamide three to five times daily. He claimed that a 
tropicamide injection enhanced the heroin effect, increased sedation, and decreased heroin related 
cravings. The second was a 38-year-old male, long term poly-drug user (heroin, codeine, 
alprazolam, ecstasy, cocaine) who also mixed heroin with up to five bottles of 1% tropicamide 
each day. Similar to the first case, he reported the enhanced and prolonged euphoric effect of 
heroin when mixed with tropicamide and reduced heroin related cravings. Both cases reported 
hallucinations, blurred vision, dizziness, decreased appetite, cognitive impairment, short term 
memory loss, and weight loss (Bozkurt et al. 2015). Prilutskaya and Kuliev (2015) commented on 
tropicamide dependence implicated clinical outcomes such as psychological dependence, 
intoxication-related psychosis, cardiovascular toxicity, and post-injection purulent soft tissue 
complications. 
Misuse and Abuse of Topical Ophthalmic Anaesthetics 
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Misuse of topical ophthalmic anaesthetics was reported in case series, case reports, and 
reviews and primarily focused on toxicity and related complications. A review by Patel and 
Fraunfelder (2013) illustrated the history of topical ocular anaesthetics, the emergent abuse of 
topical anaesthetic drops, mechanisms of toxicity, and comparison of toxicity of topical 
anaesthetics including the topical anaesthetic gels. 
Webber Frcophth et al. (1999) have reported on how topical anesthetic abuse is accepted 
as a differential diagnosis of ring keratitis. Frequent and continuous application can contribute to 
anesthetic induced keratitis (Henkes and Waubke 1978), ring keratitis (Kurna et al. 2012) and 
herpetic keratitis (Solomon et al. 1996). Bilateral corneal ring infiltrates were also described by 
Hou et al. (2009) and  Chen et al. (2004) in their reported cases where toxic keratopathy could 
occur as a result of the abuse of topical anesthetics even at very low concentrations of 0.05%. 
Dayanır et al. (2013) described the topical anesthetic abuse keratopathy and clinical progression 
in six eyes of three patients. Chern et al. (1996) reported on four cases of patients (three females 
and one male aged between 21 and 35 years) with topical anaesthetic abuse of the cornea and 
development of candida keratitis, causing severe ocular morbidity. Sugar (1998) reported on self-
medication of topical anesthetics by a female patient with corneal epithelial defects and stromal 
infiltration.  Varga et al. (1997) reported on four cases of topical anaesthetic abuse keratopathy. 
Rao et al. (2007) in Hong Kong reported on a 42-year-old female patient with keratopathy after 
progressive misuse of high dosages of oxybuprocaine eye drops, initially prescribed for post 
LASEK surgery pain.  Kintner et al. (1990) reported on two cases of infectious crystalline 
keratopathy associated with topical anesthetic abuse. Risco (1992) also reported on topical 
anesthetic keratopathy with the abuse of oxybuprocaine causing irreversible damage to the corneal 
endothelial cells. 
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Some reported studies described the treatment options for keratitis associated with topical 
anesthetic abuse. Altinok et al. (2010) suggested non-preserved amniotic membrane 
transplantation for relieving the pain and improving the corneal surface in patients with bilateral 
toxic keratopathy related to topical anaesthetic abuse. Georgakopoulos et al. (2011) discussed the 
bevacizumab role in the treatment of corneal neovascularization associated with topical anesthetic 
abuse. A case series by Burcu et al. (2013) assessed the role of early amniotic membrane 
transplantation in patients with toxic keratopathy due to topical anesthetic abuse. 
Other studies reported on initial legitimate use which progressed over time. Goldich et al. 
(2011) reported on a 47-year-old male with varied eye complications and with a history of abuse 
of oxybuprocaine resulting in keratitis. Matti and Saha (2012) reported on a 26-year-old woman 
who wore contact lens daily, usually slept without removing them, and complained of blurred 
vision, irritation, and redness in her right eye. Proxymetacaine 0.5% eye drops were applied to 
remove lenses without discomfort (Matti and Saha 2012). A case presented by Wu et al. (2016) 
sheds light on a severe case of keratopathy reported as a Mooren-like ulcer related to the abuse of 
topical anaesthetics and dexamethasone by a 38-year-old male physician who self-treated with 
tetracaine, dexamethasone (DEX), and lidocaine eye drops. Daily use was reported every hour for 
the previous six months to manage severe pain. At presentation his left cornea was melted and 
exhibited iris prolapse, where the right cornea exhibited circular melting with full-thickness 
stromal permeation. Keratoplasty was done to the patient, resulting in retained proper vision (Wu 
et al. 2016).  A case report by Kim et al. (1997) described a 29-year-old male patient with stromal 
ring infiltrates and delayed epithelial healing for a 29-year-old male who had Excimer laser 
photorefractive keratectomy (PRK) on both eyes. The patient admitted abuse of proparacaine 0.5% 
eye drops after PRK surgery. 
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Some records underscored the presence of co-morbid conditions in patients. Case series by 
Rosenwasser et al. (1990) reported on two male and four female patients, all characterized with 
ring infiltrates and some with serious intraocular inflammation.  Abuse of topical ocular 
anaesthetic was the common feature in all cases, with five out of six patients diagnosed with 
personality disorder, chemical dependency, and/or depression. This case report revealed that 
abusers obtained eye drops from ophthalmologists and pharmacies, along with thefts from clinics. 
Katsimpris et al. (2007) described five male cases admitted to the emergency unit complaining 
from corneal epithelial defects combined with a ring infiltrate in the corneal stroma as a result of 
topical anaesthetic abuse keratitis with no history of ophthalmic disease. All patients obtained the 
drugs from pharmacies without a prescription. Four patients had used proparacaine, while 
tetracaine was used by the fifth. All patients underwent a psychiatric consultation and different 
disorders were noted including depression, bipolar psychosis, substance abuse, and suicidal 
tendency (Katsimpris et al. 2007). Yeniad et al. (2010) reported on psychiatric co-morbidity in 
their eight cases, with four patients diagnosed with anxiety disorder and one with bi-polar. Toc et 
al. (2015) described that five patients (out of ten cases) were diagnosed with personality disorder, 
depression, and smoking addiction. Psychiatric disorder was associated with seven patients out of 
19 cases of topical anaesthetic abuse (Yagci et al. 2011). Erdem et al. (2013) reported on eight 
cases with psychomotor agitation  and insomnia associated with severe ocular pain and anxiety 
and half diagnosed with psychiatric conditions such as anxiety, affective disorder, and drug abuse. 
Ansari et al. (2006) discussed two female cases with a history of major depression who presented 
with ring shaped stromal opacities and large bilateral corneal epithelial defects. Both reported 
unsuccessfully self-treating with topical antibiotic to manage their topical anaesthetic associated 
keratitis. Authors reported that topical anaesthetic abuse keratopathy is usually a phenomenon of 
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underlying psychiatric disorder, and psychiatric consultation is a very critical part of treatment 
(Ansari et al. 2006). 
Occupational hazards, pharmacists’ recommendations, and availability OTC appeared 
central to some patient cohorts. The over prescription of topical anaesthetic drugs by pharmacists 
was described by Moreira et al. (1991) in Brazil. High prevalence of self-medication and abuse of 
topical anaesthetics (commonly tetracaine) among welders in Iran was reported by Sharifi et al. 
(2013), with 97.4% reporting direct sourcing from pharmacies without prescription and with low 
awareness around potential complications.  Yagci et al. (2011) in their retrospective case analysis 
of topical anesthetic abuse keratopathy underscored the need for awareness and vigilance of 
ophthalmologists. Awareness was particularly needed in young male labourers employed in the 
welding and foundry sectors and presenting with ring shaped keratitis, severe ocular pain, and 
persistent epithelial defects. Shirzadeh et al. (2016) reported on topical anaesthetic misuse in 
patients admitted to an eye clinic in Iran and observed a trend of misuse among welders who 
sourced via pharmacies without prescriptions. Eight cases of toxic keratopathy (including ring 
infiltrates) resulting from the abuse of topical anesthetic drugs were reported by Yeniad et al. 
(2010) with sourcing primarily via pharmacy dispensing without prescription. Five out of the eight 
had a corneal foreign body history, with the remainder reporting a chemical burn, ultraviolet 
radiation exposure, and a basal membrane dystrophy. On cessation of use, all clinical signs 
improved (Yeniad et al. 2010).  Toc et al. (2015) described the abuse of topical anaesthetics in ten 
males who applied 0.5% proparacaine hydrochloride to manage pain resulting from foreign bodies, 
car battery explosions, and welding flash burns experienced as occupational hazards. The majority 
sourced via community pharmacies without prescription. All presented with ring ulcer, epithelial 
defect, corneal edema, and stromal infiltration and complained from lacrimation, severe pain, and 
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photophobia. All patients underwent amniotic membrane transplantation (AMT) and achieved 
pain relief after one week (Tok et al. 2015). Similar findings in terms of occupational reasons 
contributing to misuse and abuse patterns were reported by Yagci et al. (2011), who recorded 19 
cases of topical anaesthetic abuse relating to welding flash in eight patients, metallic foreign body 
exposure in eight patients, and chemical injury in three patients. Conjunctival injection and oval 
corneal epithelial defect were reported in all 19 cases, 57.7% reported with ring-shaped keratitis, 
46.2% reported with stromal infiltrate, and 42.3% reported a hypopyon (Yagci et al. 2011). Lastly, 
Erdem et al. (2013) described eight cases, five males and three females, admitted to the cornea unit 
with keratopathy because of abusing topical anaesthetic drugs. Sourcing was described as via a 
prescription from a primary care practitioner (one) with the remainder sourcing via community 
pharmacies without prescription. Motives and reasons for use centred on traumatic corneal 
abrasion, exposure to welding flash, exposure to silica dust, and lagophthalmos-related 
keratopathy. Two had lagophthalmos associated exposure keratopathy. 
Misuse of Topical Ophthalmic Vasoconstrictive and Topically Applied Nonsteroidal Anti-
inflammatory Drugs (NSAIDs) 
Adefule‐Ositelu (1989) reported the misuse of ophthalmic agents in Nigeria, where 
vasoconstrictive eye drops are a major constituent of drugs contributing to ocular morbidity 
(Adefule‐Ositelu 1989).  Soparkar et al. (1997) reported on a case series of patients with 
conjunctival inflammation caused by excessive use of eye drops containing the vasoconstrictors 
phenylephrine, tetrahydrozoline, or naphazoline. In their study, 137 eyes for 70 patients were 
analysed. On presentation ocular symptoms were redness, itching, eyelid swelling, irritation, 
burning, pain, or foreign body sensation. Daily use patterns ranged from 1 to 12 times per day and 
from the previous 8 hours to 20 years. The most frequent pattern of conjunctivitis was conjunctival 
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hyperemia which was present in the majority of cases as an induced rebound phenomena (Soparkar 
et al. 1997). Tappeiner et al. (2009) reported on a case of a 45-year-old man who had applied 
phenylephrine eye drops hourly for years. The phenylephrine eye drops were first prescribed by a 
resident ophthalmologist, and then sourced via pharmacies without prescription.  The case 
presented with fornix shortening, eye redness, and scarring of lacrimal puncta. Ocular pemphigoid 
was excluded due to negative immunofluorescence, but neovascularization in the conjunctiva and 
signs of chronic inflammation were observed. On cessation within seven weeks complete healing 
was achieved. A second report by Flach (2001) reported on a case series of five males and six 
females with corneal melting associated with misuse and abuse of topical NSAIDs. Flach also 
reported in 2006 on three cases of corneal melting following topical use of NSAIDs (on this 
occasion bromfenac). 
Public and Pharmacist Views on Ophthalmic Drug Abuse/Misuse 
This review has highlighted the scarcity of available literature on the misuse and abuse of 
ophthalmic products in the public and community pharmacy settings. In 2005, a study was 
conducted in Bangkok to measure general population attitudes towards OTC ophthalmic remedies. 
A questionnaire was filled out by 200 members of the public. Only 93/200 (46.5%) noticed that 
the maximum allowable duration to use these preparations was only one month after opening and 
88/200 (44%) did not read the directions before use. The authors concluded that greater awareness 
is warranted in order to achieve safe public use of OTC ophthalmic preparations (Tayanithi and 
Aramwit 2005). In 2011, an interview based study was conducted in India to measure how OTC 
ophthalmic drops could be misused by customers and to gain a better understanding of their 
attitudes, knowledge, and triggers for misuse of such medications (Kadri et al. 2011). Data also 
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included type of OTC ophthalmic drops, duration and indication for use, pharmacist role in 
counselling and the status of their condition as improved or declined. Findings illustrated a lack of 
customer awareness, with the majority of patients indicating no knowledge about the choice of 
OTC and prescription ophthalmic products. Misuse and abuse was reported mainly due to 
inadequate knowledge of dangerous side effects occurring from excessive use (Kadri et al. 2011). 
In terms of pharmacist attitudes, a study conducted in India investigated perceptions around 
how OTC ophthalmic drops were misused (Kadri et al. 2010).  There were 89 pharmacists that 
completed a semi-structured questionnaire, and the results were that the average number of patients 
attending community pharmacies complaining from ophthalmic problems was seven per day, with 
the main complaint being redness and itching of the eye. The most common eye drops dispensed 
were antibiotics (96.6%), steroids (55.1%), decongestants (54.1%), steroid-antibiotic 
combinations (29.2%), and lubricants (16.8%). Knowledge of steroid side effects was observed 
only in 40.6% pharmacists, and 6.7% pharmacists had noticed some of the side effects resulted 
from eye drop preparation when misused or abused by their patients. The study highlighted that 
educating the public and pharmacists about these remedies may reduce the ocular complications 
and improve safety of use (Kadri et al. 2010). A recent survey in Jordan has revealed that 
ophthalmic drug abuse sourced from community pharmacies is on the rise (Wazaify et al. 2016). 
In 2016, a study was conducted which investigated the knowledge, attitudes, and experience of 
community pharmacists regarding misuse and abuse of ophthalmic drops. A structured 
questionnaire was completed by 220 pharmacists. The majority of ophthalmic drugs were reported 
to be dispensed without a prescription (61.85%). Five OTC drops and two prescription-only 
products were reported by pharmacists to be liable for abuse. With regard to management of the 
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problem, 69.5% of pharmacists refused to sell the product and claimed that the drug was 
unavailable (Wazaify et al. 2017). 
Discussion 
This paper is the first known attempt to scope and map the extant literature on the topic of 
misuse and abuse of ophthalmic drugs. The abuse of ophthalmic anticholinergic drugs is related to 
their effect in causing euphoria, relaxation, hallucination, and reduction of depression symptoms 
(Darcin et al. 2011; Bersani et al. 2013; Bersani et al. 2015). A range of health harms are observed 
in the literature. Studies on the abuse of ophthalmic drugs report associated outcomes of ocular 
toxicity, impaired vision, uveitis, and blindness (Darcin et al. 2011; Kadri et al. 2010). Different 
ocular disorders have been associated with the abuse of these drugs, including keratopathy, stromal 
infiltrates, persistent epithelial defects, and secondary infectious keratitis and may lead to corneal 
melting, permanent visual loss, and perforation (Rosenwasser et al. 1990;  Chern et al. 1996; Flach 
2001; Yeniad et al. 2010; Hendershot et al. 2011; Erdem et al. 2013; Sharifi et al. 2013; Tok et al. 
2015). Misuse of topical ophthalmic anaesthetics causes anesthetic induced keratitis (Henkes and 
Waubke 1978; Webber Frcophth et al. 1999; Goldich et al. 2011; Kurna et al. 2012; Matti and 
Saha 2012; Wu et al. 2016), bilateral corneal ring infiltrates (Rapuano  1990; Katsimpris et al. 
2007), toxic keratopathy (Risco 1993; Varga et al. 1997; Chen et al. 2004; Rao et al. 2007; 
Kirikkaya et al. 2013), candida keratitis (Chern et al. 1996), stromal infiltration (Sugar 1998; Kim 
et al. 1997), and infectious crystalline keratopathy (Kintner 1990). Acute and chronic 
conjunctivitis generally occur as a result of the excessive use of ophthalmic decongestants 
(Soparkar et al. 1997; Tappeiner et al. 2009; Kadri et al. 2010). Conjunctivitis rebound phenomena 
and chronic inflammation have been reported in patients misusing eye drops containing the 
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vasoconstrictors phenylephrine, tetrahydrozoline, or naphazoline (Soparkar et al. 1997; Tappeiner 
et al. 2009). 
Systemic absorption of these drugs can also happen and lead to psychosis and/or 
hallucinations if used in high doses and for prolonged periods of time (Balbani et al. 2000). 
Additional patient vulnerability to co-morbid conditions such as personality disorder, bi-polar 
disorder, anxiety disorder, chemical dependence, depression, and suicidal ideation are evident 
(Rosenwasser 1990; Ansari et al. 2005; Katsimpris et al 2007; Yeniad et al. 2010; Yagci et al. 
2011; Erdem et al. 2013; Toc et al. 2015). Therefore, psychiatric diagnosis is a vital component of 
the clinical care pathway (Ansari et al. 2005). Drug induced toxicity in the case of abuse of 
cycloplegic and mydriatic ophthalmic drugs contribute to keratitis with some reports around 
withdrawal symptomatologies and difficulties in the treatment of dependence (Ostler 1975; Sato 
et al. 1992; Akkaya 2008; Darcin et al. 2011). Cyclopentolate systemic side effects reported in the 
literature range from inappropriate behaviour, visual and auditory hallucinations, changes in 
emotional attitude, and generalized seizures to a lesser extent (Rajeev et al. 2010; Bhatia et al. 
2000). Cognitive impairment and weight loss are common (Bersini et al. 2015). IV injections of 
tropicamide were reported in heroin users to intensify the effect and when self-medicating to delay 
withdrawals (Spagnolo et al. 2013; Bersani et al. 2013; Bozkurt et al. 2014; Prilutskaya and Kuliev 
2014, 2015; Bersani et al. 2015; Otiashvili et al. 2016; Ponté et al. 2017). These injections are 
concerning, particularly given the clinical outcomes such as psychosis, dependence, injecting 
harms, and cardiovascular toxicity (Prilutskaya and Kuliev 2014, 2015). Particularly among IV 
injectors of tropicamide, poly-drug use is common and associated with psychiatric co-morbidities 
(Bersani et al. 2015). 
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Occupational hazards and the availability of OTC drugs appeared central to some patient 
cohorts such as welders and labourers (Yeniad et al. 2010; Yagci et al. 2011; Sharifi et al. 2013; 
Erdem et al. 2013; Toc et al. 2015; Shirzadeh et al. 2016). Sourcing of topical anaesthetics via the 
ophthalmologist and pharmacy, along with diversion via theft were described (Rosenwasser et 
al.1990; Katsimpris et al. 2007; Yeniad et al. 2010; Yagci et al. 2011; Erdem et al. 2013; Toc et 
al. 2015; Shirzadeh et al. 2016).  
Generally, public and pharmacy awareness of the issue of misuse and abuse of ophthalmic 
drugs remains low and warrants targeted efforts to inform both parties regarding ocular 
complications, safe use, and consequences of misuse (Tayanithi and Aramwit 2005; Kadri et al. 
2010; Kadri et al. 2011; Wazaify et al. 2017). The studies where available have highlighted the 
need for ophthalmologist and community pharmacist awareness and training for recognising and 
intervening where potential misuse and abuse of ophthalmic products is suspected. (Rapuano 1990; 
Sugar 1997; Bozkurt et al. 2015).  
 
Conclusion 
This review underscores the complexities around motives for misuse and abuse of a range 
of ophthalmic drugs, availability of OTC ophthalmic products, self-medication practices, presence 
of co-morbidities, and low public awareness around harms highlighting the important role of health 
professionals regarding suspected misuse of these common products. Further research is warranted 
to investigate abuse limit of these ophthalmic drugs and potential regulatory efforts to address the 
issue.   
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